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Abstract 
Angiogenesis is essential for the growth and metastasis of solid tumors. The tumor endothelium exists in a state of 
chronic activation and proliferation, fueled by the tumor milieu where angiogenic mediators are aberrantly over-
expressed. Uncontrolled tumor growth, immune evasion, and therapeutic resistance are all driven by the dysregulated 
and constitutive angiogenesis occurring in the vasculature. Accordingly, great efforts have been dedicated toward 
identifying molecular signatures of this pathological angiogenesis in order to devise selective tumor endothelium tar-
geting therapies while minimizing potential autoimmunity against physiologically normal endothelium. Vaccination 
with angiogenic antigens to generate cellular and/or humoral immunity against the tumor endothelium has proven 
to be a promising strategy for inhibiting or normalizing tumor angiogenesis and reducing cancer growth. Here we 
review tumor endothelium vaccines developed to date including active immunization strategies using specific tumor 
endothelium-associated antigens and whole endothelial cell-based vaccines designed to elicit immune responses 
against diverse target antigens. Among the novel therapeutic options, we describe a placenta-derived endothelial cell 
vaccine, ValloVax™, a polyvalent vaccine that is antigenically similar to proliferating tumor endothelium and is sup-
ported by pre-clinical studies to be safe and efficacious against several tumor types.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Angiogenesis, the outgrowth of new blood vessels from 
pre-existing capillaries and post-capillary venules, occurs 
during embryonic development, in the uterus during 
the menstrual cycle, in the process of wound healing, 
and in pathological conditions [1]. In healthy adults, 
endothelial cells can maintain a quiescent state for years, 
whereas they proliferate and migrate to form new ves-
sels in response to inflammatory conditions and during 
tumor growth. Several studies have estimated that tumor 
associated endothelial cells proliferate 30–40 times faster 
relative to endothelial cells found in healthy vascula-
ture [2–4]. Based on estimates that tumors fail to grow 
beyond 1–2 mm in the absence of new capillary growth, 
Dr. Judah Folkman put forth the central hypothesis that 
tumors release diffusible factors that stimulate endothe-
lial cell proliferation in host capillary blood vessels [5]. 
Indeed, it has been estimated that eradication of one 
endothelial cell is capable of neutralizing of up to 100–
300 tumor cells [6]. Since the immune system is in direct 
contact with the tumor vasculature, vaccination against 
tumor endothelium is theoretically very promising for 
breaching the immunological barriers created by the 
tumor microenvironment.
The goal in vaccination strategies is to raise immunity 
against antigens present in tumor endothelium while 
avoiding antigens that cross-react with healthy vascula-
ture, thereby preventing deleterious autoimmune reac-
tions. Since the landmark publication by Dr. Folkman, 
a catalog of molecular players involved in the process 
of tumor angiogenesis have been identified and charac-
terized. However, clinical outcomes of traditional anti-
angiogenic therapies such as monoclonal antibodies have 
improved patient survival rates only modestly [7]. Vac-
cination against endothelial cells is poised to overcome 
the existing problems of drug resistance and adverse 
side effects associated with other approaches. This 
report reviews vaccination strategies against the tumor 
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endothelium that have been tested to date, including 
DNA, protein and peptide vaccines of tumor-endothe-
lium-associated antigens, as well as polyvalent vaccines 
comprised of whole endothelial cells. Very encouraging 
data point toward the efficacy of vaccination in raising 
humoral and cell-mediated immunity against angiogen-
esis-associated antigens in cancer. In this discussion, we 
also highlight our novel approach wherein placenta-
derived endothelial cell lysates (ValloVax™) are used as 
a source of antigen for vaccinating against proliferating 
tumor endothelial cells.
How do angiogenic factors affect the tumor 
endothelium?
Endothelium is a dynamic and heterogeneous structure 
influenced by environmental factors such as shear stress, 
oxygen content of the blood, chemokines, cytokines, 
and changes in the content of the extracellular matrix 
[8]. Whereas resting endothelium serves to maintain 
blood fluidity, regulate blood flow, control vessel wall 
permeability, and quiesce circulating lymphocytes [9], 
environmental cues activate endothelial cells to prolifer-
ate, migrate, and form new branches (sprouting). In the 
tumor milieu, aberrantly elevated and chronic produc-
tion of angiogenic factors leads to endothelial activation, 
vascular irregularities, and immune suppression, which 
are among the well-recognized hallmarks of cancer pro-
liferation [10]. Whereas the structure of normal vascular 
endothelium is hierarchical and organized, the activated 
endothelium in cancer consists of dilated and tortuous 
blood vessels that are chaotically interconnected, lead-
ing to heterogeneous vessel density within the tumor, 
erratic blood flow, and focal regions of hypoxia [11, 12]. 
At the cellular level, tumor endothelial cells display a 
disorganized morphology, being loosely connected and 
exhibiting increased vascular permeability [13]. These 
conditions cause impaired oxygen and nutrient delivery, 
conditions which in turn trigger angiogenesis, thereby 
further promoting tumor endothelial cell activation and 
vascular growth to meet the metabolic demands of the 
tumor. In this manner, cancer cells and endothelial cells 
are involved in a positive feedback loop stimulating each 
other’s growth. At the same time, the vascular malforma-
tions in the tumor milieu serve as obstacles to effective 
penetration of anti-tumor lymphocytes and chemother-
apy drugs into the tumor mass.
Although tumor endothelial cells are considered to be 
genetically stable as compared to tumor cells, angiogenic 
factors can fuel genetic aberrations of tumor endothe-
lium. Indeed, resistance of tumor endothelial cells in 
diverse cancers has been described; for example, tumor 
endothelial cells in renal carcinoma are reportedly resist-
ant to serum starvation [14], breast tumor endothelial 
cells are resistant to vincristine-induced apoptosis [15] 
and hepatocellular carcinoma endothelial cells are resist-
ant to 5-fluorouracil and doxorubicin [16]. One study 
demonstrated aneuploid chromosomes and abnormal 
centrosomes in tumor endothelial cells [17]. Signal-
ing in response to the dysregulated over-production of 
angiogenic factors, including vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF), in 
absence of endothelial stability promoting factors such 
as PDGF-BB was found to contribute to aneuploidy 
and centrosome duplication in tumor endothelial cells 
[18]. Moreover, tumor endothelial cells with excess cen-
trosomes exhibit apoptosis resistance and formation of 
aberrant spindle projections, likely attributable to gain or 
loss of genes involved in proliferation, survival, and adhe-
sion [18]. At the mechanistic level, VEGF secreted from 
tumors affects tumor endothelial cells by upregulating 
MDR1, a gene encoding a transmembrane glycoprotein 
P-gp that is known as a multidrug transporter that poten-
tiates resistance to several anti-cancer agents [19]. For 
example, paclitaxel, which is used to treat several types 
of cancer together with anti-angiogenic drugs, is trans-
ported by P-gp. The VEGFR kinase inhibitor, Ki8751, and 
a phosphatidylinositol 3-kinase–Akt inhibitor, LY294002, 
effectively block tumor-induced MDR1 up-regulation, 
suggesting that VEGF in the tumor microenvironment 
is an underlying factor in acquired drug resistance [19]. 
Vaccination against angiogenesis-associated antigens 
therefore could serve as a valuable asset for improving 
the efficacy of other cancer therapeutics.
Heterogeneity among tumor endothelial cells, as cho-
reographed by the over-activity of certain angiogenic 
pathways, also shields tumors by affecting their vis-
ibility to the immune system. Production of angiogenic 
molecules by tumors inhibits the expression of adhe-
sion molecules involved in leukocyte interactions with 
blood vessel walls, including intercellular adhesion mol-
ecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1), E-selectin and CD34 [20]. These features of 
tumor endothelium prevent adhesion and extravasation 
of effector T cells into the tumor. Additionally, tumor 
endothelial cells have been described as anergic, marked 
by unresponsiveness to inflammatory cytokines that 
would normally induce adhesion molecule expression 
but instead allow the endothelium to escape immune 
surveillance [20, 21]. The anergic phenotype of tumor 
endothelial cells can be reversed by anti-angiogenesis 
therapy, which upregulates the expression of endothelial 
adhesion molecules in the tumor vasculature [22, 23]. 
The tumor endothelium is also prohibitive to entry of 
tumor-reactive T lymphocytes by suppression or direct 
killing of effector T cells via molecules such as Fas ligand 
(FasL) [24]. Notably, VEGF-A, interleukin 10 (IL-10) and 
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prostaglandin E2 (PGE2) are involved in eliciting FasL 
expression in endothelial cells, as evidenced by observa-
tions that pharmacological inhibition of these molecules 
leads to a marked influx of tumor-rejecting CD8+ cells 
and tumor growth suppression in mice. Hence, anti-
angiogenesis vaccination can break down the immuno-
logical firewall that the tumor endothelium imposes to 
protect the cancer.
Approaches for vaccinating against tumor 
endothelium‑associated antigens
Cancer vaccines consist of tumor-associated antigens 
delivered in a pro-inflammatory context to generate 
potent antitumor immune responses and overcome the 
cancer’s varied immunosuppressive mechanisms. Vac-
cination strategies directed against tumor-associated 
endothelium are designed to take advantage of both 
quantitative and qualitative differences between tumor 
endothelial cells and non-malignant endothelial cells. 
Ideal vaccine candidates include receptors/proteins that 
are upregulated in tumor endothelium, owing to its acti-
vated and proliferating state, but are sparsely expressed 
during physiological angiogenesis in healthy adult tis-
sues. Notably, angiogenesis-associated molecules can 
be over-expressed on endothelial cells in an organ- or 
tumor-specific manner, and can sometimes be expressed 
on resting endothelial cells [25]. Thus, an attractive 
tumor endothelial vaccine should be capable of elicit-
ing anti-angiogenesis and anti-cancer immunity against 
diverse tumor types, while avoiding autoimmune reac-
tions against physiological angiogenesis, such that occur 
in the female reproductive tract and during wound heal-
ing, or against quiescent endothelium.
Whether immunity and/or autoimmunity ensue as a 
result of vaccination is dependent not only on the target 
tumor endothelial antigen but also on the vaccination 
protocol. Candidate vaccines have employed numerous 
delivery approaches, including proteins, peptides, den-
dritic cells pulsed with the antigen(s), naked DNA or 
recombinant DNA delivered by carriers, and mRNA vac-
cines, as well as whole cell vaccines or endothelial mem-
brane components. To develop rationales for clinical 
vaccine design, pre-clinical studies have been conducted 
for many angiogenesis-associated molecules using vari-
ous delivery systems. In some cases, differences in safety 
and efficacy between vaccines hinge on a plethora of sec-
ondary variables including the use of different delivery 
vectors, the choice of adjuvants and the varying routes of 
vaccine administration.
Two general approaches to anti-angiogenesis vacci-
nation have yielded promising results for inducing spe-
cific and robust immunity against tumor endothelium 
and reducing tumor growth and metastasis: (1) vaccines 
expressing defined angiogenesis-associated antigens; and, 
(2) vaccines comprised of whole endothelial cells and/or 
mixtures of endothelial antigens. In the latter category 
are vaccines consisting of placenta-derived endothelial 
antigens, an approach currently being advanced by Batu 
Biologics, Inc. (ValloVax™ vaccine).
Vaccines targeting defined 
angiogenesis‑associated antigens
Evidence has shown the feasibility of targeting molecules 
that are expressed by angiogenic endothelium, and the 
data also suggest that anti-angiogenic vaccination can be 
applied synergistically with tumor immunotherapy and/
or chemotherapy to invoke anti-tumor immunity. Theo-
retically, the approach of targeting certain defined angio-
genesis-associated molecules on tumor endothelium has 
the risk to evoke only a transient decrease in cancer pro-
gression, owing to the fact that angiogenesis can proceed 
via compensatory pathways. Despite this caveat, success 
at achieving anti-angiogenic immunity has been demon-
strated by vaccinating against the following antigens.
VEGF‑A and VEGFR
VEGF/VEGFR is perhaps the best-studied angiogenic 
pathway involved in the growth and survival of tumor 
endothelium. Clinical therapies addressing tumor angi-
ogenesis have therefore largely focused on inhibiting 
VEGF and its cognate receptor. VEGF-A exists in sev-
eral pro-angiogenic variants that are secreted by both 
tumor cells and endothelial cells and activate VEGFR1 
and VEGFR2. Numerous VEGF-expressing vectors 
have been administered for vaccinating against VEGF. 
A Xenopus VEGF DNA vaccine that was protective and 
therapeutic in several tumor models in mice, an effect 
that was mediated by anti-tumor activity of CD4+ lym-
phocytes [26]. A phase I clinical study has investigated 
CIGB-247, a vaccine comprising a human VEGF vari-
ant molecule in combination with a bacterial adjuvant, 
in 30 patients with advanced solid tumors [27]. After 
eight consecutive weeks of subcutaneous immunization 
and re-vaccination on week 12, this vaccine was safe 
at three dose levels and also demonstrated immuno-
genicity in three sequential analyses of patients’ blood 
samples. Despite the critical importance of VEGF in 
hematopoiesis [28–30], no abnormalities in leukocytes 
or megakaryocytes were found, and additionally, serum 
biochemistry parameters were not altered in patients 
received the VEGF vaccination. Based on this clinical 
report, VEGF is a highly promising vaccine target as a 
cancer treatment strategy. The implications of this body 
of research are that immunity can be induced to self-
antigens, without triggering a fulminant autoimmune 
response.
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VEGFR2 (also FLK-1 and KDR), which is highly 
expressed on proliferating endothelial cells of the tumor 
vasculature, has also been the focus of numerous pre-
clinical studies. Animal models using VEGFR2 DNA, 
protein, and peptide vaccines have demonstrated their 
ability to elicit potent humoral and cellular immunity, 
suppression of angiogenesis, tumor necrosis and/or sup-
pression of metastastatic progression [31–38]. Interest-
ingly, none of the aforementioned studies have reported 
hematopoietic or other abnormalities.
Since VEGFR2 is also expressed at lower levels in 
normal vascular endothelium, vaccination could theo-
retically cause side effects or an autoimmune response. 
Neithammer et  al. reported that in murine models a 
DNA vaccine against VEGFR2 suppressed angiogenesis 
in the tumor vasculature as verified by in vitro inhibition 
of endothelial cell proliferation, deposition of antibodies 
in tumor vasculature, a reduction of microvessel density 
and antitumor activity in  vivo without impairment of 
fertility, neuromuscular performance or hematopoiesis; 
however, a slight delay in wound healing in immunized 
mice was noted [39]. In another report, there was no 
delay in wound healing observed in response to a den-
dritic cell-based VEGFR2 vaccine although reduced lit-
ter sizes and fetal loss were found in vaccinated animals 
[40]. However, in other studies where VEGFR2 protein 
vaccines were found to generate potent immunity against 
tumor endothelium, no effects on wound healing, repro-
duction or other organ toxicities were observed [35, 41].
Immunogenic epitopes of VEGFR2 have been identi-
fied and peptide vaccines have been optimized for bind-
ing to MHC class I molecules in order to elicit activity 
of cytotoxic T lymphocytes (CTL) specific for tumor 
endothelium. In a clinical study of pancreatic cancer, 
administration of immunogenic VEGFR2-169 peptide 
vaccine in combination with gemcitabine was well tol-
erated with no severe adverse events and peptide-spe-
cific CTL were induced [42]. Other than injection site 
reactions, other peptide vaccines tested for targeting 
VEGFR were also deemed to have manageable toxicities 
[43–45].
bFGF and FGF‑R
Basic fibroblast growth factor (bFGF or FGF-2) and its 
receptor (FGFR-1, CD331) have been targeted in pre-
clinical mouse models to evaluate their anti-angiogenic 
and anti-tumor effects. FGFR-1 is highly expressed on 
angiogenic endothelium as well as on endothelial pro-
genitor cells [46, 47]. In one such study, vaccination 
with xenogeneic FGFR-1 plasmid DNA inhibited tumor 
endothelial cell proliferation and produced anti-cancer 
immunity in three murine tumor models [48]. Studies 
utilizing recombinant protein vaccines targeting FGFR-1 
demonstrated significantly decreased tumor volume 
compared to controls, as well as decreased microvessel 
density in tumors without any observable overt toxicity 
[49]. Peptide bFGF vaccines combined with adjuvants 
also induced antigen-specific antibody and cell-mediated 
responses [50, 51]. Importantly, in a study where a lipo-
some-based peptide bFGF vaccine was administered in 
murine cancer models, immunity against tumor endothe-
lium was elicited while physiological angiogenesis was 
unperturbed, as evidenced by normal wound healing 
times and no impairments in the reproductive ability of 
vaccinated animals or in the viability or health of the off-
spring [52].
αvβ3
The expression of several cell adhesion molecules, most 
notable integrin alpha(v)beta(3), has been associated 
with tumor angiogenesis [53].
Integrin αvβ3 plays a role in several physiological pro-
cesses including angiogenesis, pathological neovascu-
larization, and tumor metastasis [53]. An αvβ3 ligand 
vaccine induced a humoral response associated with sig-
nificant antitumor activity without recourse of adjuvant 
therapy. The immune response was driven by antibody-
dependent cellular toxicity and complement-directed 
cytotoxicity to the tumor-associated endothelial cells 
[54]. The effectiveness of utilizing antibodies block-
ing αvβ3 as a method of inhibiting angiogenesis, has led 
to the clinical development of monoclonal anti-αvβ3 
antibodies for the treatment of advanced solid tumors. 
MEDI-522, a second generation humanized anti-αvβ3, 
successfully completed a Phase I study in patients with a 
variety of metastatic solid tumors, and a maximum toler-
ated dose was not identified by traditional dose-limiting 
toxicities [55].
Angiomotin
Another target of anti-angiogenic vaccine strategies is 
the angiostain binding protein angiomotin, a membrane-
associated pro-angiogenic protein present on endothe-
lial cells in angiogenic tissues [56]. Holmgren et al. used 
DNA vaccination with a xenogeneic (human) angiomotin 
DNA construct to increase immunogenicity of the vac-
cine, and injected the DNA intramuscularly followed by 
electroporation [57]. This vaccine protected mice from 
tumor challenge and acted synergistically with a vac-
cine targeting the Her-2 oncogene in a transgenic breast 
cancer model system. No evidence for autoimmunity 
in normal vasculature of the retinas was noted at 16 or 
70 weeks post-treatment. In another report, an angiomo-
tin DNA vaccine was shown to alter blood vessel archi-
tecture to increase permeability and thus improve the 
efficacy of chemotherapy in an animal model [58].
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Endoglin (CD105)
This transmembrane glycoprotein is primarily 
expressed in proliferating endothelial cells and is 
upregulated by hypoxia; therefore, endoglin is strongly 
expressed in tumor endothelial cells [59]. The func-
tional role for endoglin in hematopoiesis is also exem-
plified by CD105 knockout studies where embryonic 
lethality occurred as a result of impaired angiogen-
esis in the yolk sac and heart defects. CD105 expres-
sion on tumor vessels is a prognostic factor correlated 
with poor overall and disease-free survival, tumor 
recurrence, and metastasis of various cancers [60, 61]. 
CD105 vaccination approaches employing bacterial 
surface display of protein [62] and orally administered 
DNA vaccines [63] effectively targeted the vasculature 
and inhibited tumor growth in the absence of observ-
able effects on healthy tissues.
Survivin
This is an intracellular tumor-associated antigen that is 
upregulated in cancers and tumor endothelial cells but 
is not expressed in healthy differentiated tissues. Sur-
vivin is a member of the inhibitor of apoptosis protein 
family, and serves to inhibit programmed cell death, 
promote cellular proliferation and enhance angiogenesis 
[64]. Survivin vaccines elicit apoptosis of tumor cells and 
its vasculature with variable efficacy; while intradermal 
electroporation was found to be very effective in animal 
models, naked DNA administration is less effective in the 
prophylactic or therapeutic settings [65, 66].
Robo4
Robo4 is a member of the Roundabout family proteins 
and is a transmembrane cell adhesion molecule that is 
specifically expressed in endothelial cells and hematopoi-
etic stem cells and progenitor cells [67]. Robo4 guides the 
formation of the vasculature by controlling endothelial 
cell migration and coordinating blood vessel sprouting 
[68]. Tonic Robo4 signaling in healthy tissues maintains 
vascular integrity by inhibiting VEGF-induced endothe-
lial cell migration and vascular permeability [69]. Robo4 
is pathologically over-expressed in the tumor endothe-
lium [70], it promotes atypical vascular patterning that 
reduces blood-tumor barrier permeability, thereby likely 
impeding the access of chemotherapy drugs to tumors 
[71]. In one study, a protein vaccine against this target 
was developed, comprised of the extracellular domain of 
mouse Robo4, fused to the Fc domain of human immu-
noglobulin within an adjuvant. Vaccinated mice had a 
strong antibody response to Robo4, impaired fibrovas-
cular invasion in vitro, and reduced growth of implanted 
Lewis lung carcinoma [72]. Further studies will be 
needed to determine how breaking tolerance to Robo4 
affects physiological angiogenesis, where it appears to 
counteract angiogenic signaling [73].
Tie‑2/angiopoietin receptor
Tie-2 is an endothelium-specific receptor tyrosine 
kinase that binds to angiopoietin and is upregulated on 
diseased endothelium in diverse conditions including 
cancer, atherosclerosis, and macular degeneration. A 
protein vaccine based on chicken Tie-2 reduced growth 
of hepatomas and melanomas in mice, whereas a murine 
Tie-2 vaccine was ineffective, indicating the need for 
further enhancement of this protein’s immunogenicity 
[74]. The chicken Tie-2 vaccine exhibited apoptotic and 
anti-angiogenic effects on endothelial cells. The ligand 
for Tie-2, angiopoietin-2 is also over-expressed during 
neoangiogenesis in tumors and acts synergistically with 
VEGF in promoting tumor vascularization [75].
EGFR
This receptor can be activated by diverse ligands; namely, 
EGF, transforming growth factor-α (TGF-α), amphiregu-
lin, betacellulin, heparin-binding EGF, or epiregulin that 
are locally secreted by cancer cells and can act in an auto-
crine fashion. EGFR signaling regulates the secretion of 
several different angiogenic growth factors by tumor cells 
including VEGF [76]. Co-expression of EGFR ligands and 
EGFR is associated with malignant tumor phenotypes 
and poor prognosis in cancer patients [77–79]. Monoclo-
nal antibodies and vaccines targeting this pathway have 
been implemented clinically, including the monoclonal 
antibodies cetuximab, panitumumab and nimotuzumab; 
the small tyrosine kinase molecules erlotinib and gefi-
tinib; the EGF-based cancer vaccine CIMAvax®; and a 
EGFR-based HER-1 cancer vaccine. CIMAvax-EGF is a 
therapeutic cancer vaccine of human recombinant epi-
dermal growth factor (EGF) conjugated to a carrier pro-
tein from Neisseria meningitides. The vaccine induces 
antibodies against EGF and confers a survival advantage 
in patients with non-small-cell lung cancer [80]. Studies 
of post-operative wound healing revealed that there are 
no deleterious effects on physiological angiogenesis asso-
ciated with targeting the EGF pathway [81] (Fig. 1).
HP59
This polypeptide is expressed as a marker for neonatal 
lung vasculature and adult pathological angiogenesis. 
HP59 protein has been identified in the vasculature of 
many types of tumors including lung, colon, ovary, and 
breast cancers of different stages, but not in the corre-
sponding normal tissues; therefore, this protein could 
be an ideal target antigen for vaccinating against tumor 
endothelium [82]. Vaccination of mice with immuno-
genic HP59 peptides attenuated the growth of Lewis lung 
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tumors and inhibited pathological angiogenesis, as evi-
denced by an absence of HP59-expressing blood vessels. 
HP59 possesses a 41-amino acid sequence at the NH2 
terminal that has no homology with any known protein; 
therefore, this antigen could be used for raising specific 
immunity against the pathological vasculature in human 
cancer [82].
PDGFRβ
This tyrosine kinase receptor is activated by members of 
the platelet-derived growth factor family, and is broadly 
involved in regulating cellular proliferation and differen-
tiation in physiological and pathological contexts. PDGF-
B, the ligand, produced by tumor cells binds to PDGFR 
on stromal and perivascular cells to promote tumor 
growth and angiogenesis, as well as eliciting other path-
ways of tumor nourishment [83, 84]. PDGFRβ supports 
angiogenesis in two distinct ways: (1) by activating peri-
cytes, which support endothelial cell proliferation and 
elaboration of the tumor vasculature; and (2) by upreg-
ulating expression of the proangiogeneic factor FGF-2 
[84].
Anti-PDGF drugs have been widely used for treating 
various cancers; however, their mechanisms of action at 
a molecular level are not strictly anti-angiogeneic. Para-
doxically, PDGF ligand inhibition can increase tumor 
angiogenesis, which supports increased tumor growth 
but, in doing so, normalizes blood vessel walls to allow 
for more efficient delivery of chemotherapy drugs [85, 
86]. On this basis, inhibiting the PDGF pathway can 
serve as an effective adjunct to cytotoxic drugs and yield 
a net gain in eradicating tumors [85].
To assess the effects of vaccinating against PDGFRβ, a 
DNA vaccine delivered via Salmonella typhimurium was 
given to mice orally in murine colon, breast and lung car-
cinoma model systems [87]. Significantly, in a therapeutic 
setting where tumors were implanted 20 days before vac-






















Tumor-derived factors change endothelial cell phenotype 
and reprogram immune cells to promote angiogenesis, 

















Fig. 1 Unique structure of tumor vasculature. The tumor vasculature is identified by several irregular characteristics: they are leaky, fragile with 
many holes and tears, and have chaotic blood flow. These structural differences in the tumor endothelial cells reflect a fundamental change in 
endothelial cell phenotype when in the presence of tumor secreted factors such as: VEGF, TGF-B, IL-4, IL-10, FGF, and many other cytokines/growth 
factors. This change in phenotype can be characterized by the upregulated expression of several related angiogenesis markers that have relatively 
low expression on healthy endothelium in vivo
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group was one-fourth the size of the control group. Angi-
ogenic markers within tumors were reduced and robust 
cytotoxic T cell responses against PDGFR-β were detect-
able, indicating that angiogenesis was effectively targeted.
TEM1
Tumor endothelial marker 1, also known as endosialin or 
CD248, is a type 1 membrane protein involved in devel-
opmental, physiological and pathological angiogenesis. 
TEM1 is overexpressed in the vasculature of carcino-
mas, brain tumors and sarcomas [88–91] and is present 
on endothelial cells, pericytes, and fibroblasts [92, 93]. 
A DNA vaccine expressing full-length mouse Tem1 
cDNA fused to tetanus toxoid adjuvant inhibited tumor 
growth and progression without affecting reproduction 
or wound healing [94]. Splenocytes from TEM1 vacci-
nated mice secreted IFN-γ and lysed TEM1-expressing 
endothelial cells in  vitro. These data support the use of 
TEM1 protein vaccine in conjunction with an adjuvant to 
break tolerance to tumor endothelium for the treatment 
of solid tumors.
TEM8
Designing a tumor endothelial vaccine based on TEM8 is 
a very enticing possibility since this molecule is selectively 
upregulated on tumor endothelial cells and, unlike the 
majority of other putative vaccine targets, TEM8 is unde-
tectable in endothelium during physiological angiogenesis 
[95]. The first TEM8 DNA vaccine was a syngeneic vaccine 
that was tested in a rat model of breast cancer and murine 
melanoma [96]. Although the vaccine had no activity as 
a single agent, TEM8 DNA significantly enhanced anti-
tumor immunity when administered with a rat HER2 DNA 
vaccine for breast cancer, and also in combination with 
a tyrosine-related protein-1 DNA vaccine in melanoma. 
Ruan et  al. developed a xenogeneic TEM8 DNA vaccine 
carried by xenogeneic Salmonella typhimurium that was 
capable of generating TEM8-specific CD8+ cytotoxic 
T cells and protected mice from lethal tumor challenge 
[97]. Another vaccination approach consisted of dendritic 
cells transduced with recombinant adenovirus encoding 
TEM8, which also effectively protected mice from lethal 
challenges against hepatocellular carcinoma [98]. Lastly, 
a DNA vaccine encoding syngeneic TEM8 and murine 
beta-defensin 2, which activates dendritic cells to stimu-
late potent immunity, was used to inhibit tumor growth in 
a murine colon cancer model [99]. This vaccine was also 
highly effective, causing the collapse of tumor vessels by 
evoking an antigen specific CD8+ T cell response. Further 
studies are warranted to determine whether TEM8-based 
vaccines can be safe and efficacious for clinical use.
In summary, several therapeutic approaches have been 
explored targeting single antigen expressed on the tumor 
endothelium, demonstrating the feasibility of targeting 
the tumor vasculature by vaccine therapy without induc-
ing systemic autoimmunity to quiescent endothelium 
in  vivo. Signals of efficacy have been observed in pre-
clinical studies around these targets, and several tumor 
endothelium-targeting vaccines have made it into the 
clinical setting for the treatment of cancer. As such, in an 
effort to reduce the development of treatment resistance 
and to potentiate the strength of an immune response 
and resultant survival benefit, the authors would like to 
explore the concept of a polyvalent vaccine targeting sev-
eral angiogenesis associated antigens.
Endothelial cell vaccines
Although great strides have been made in advancing anti-
angiogenesis tumor vaccines against specific targets, it is 
clear that the presence of many interrelated and compen-
satory pathways, as well as genetic instability of tumor 
endothelium could theoretically overcome targeted inhi-
bition in a clinical setting. Accordingly, polyvalent vac-
cination approaches are being developed using whole 
endothelial cells or isolated proteins from endothelial 
cell membranes. Another advantage of such polyvalent 
vaccines expressing numerous angiogenic antigens is 
to allow antigen-presenting cells to process and present 
immunodominant epitopes for generating anti-angio-
genic immunity.
Preclinical studies of endothelial cell vaccines
Human umbilical vein endothelial cells (HUVEC) have 
been the standard for cell-based models of tumor angio-
genesis, having the ability to proliferate extensively and 
expressing a number of pro-angiogenic molecules that 
mimic tumor neovasculature. Specifically, the aforemen-
tioned antigens such as VEGFR2, αvβ3 and endoglin, 
which are common biomarkers associated with tumor 
angiogenesis, are expressed in the primary culture of 
HUVECs [100]. In a report by Wei et al. [100], paraform-
aldehyde fixed xenogeneic whole HUVEC used as a vac-
cine markedly inhibited tumor growth in prophylactic 
and therapeutic murine cancer models. The anti-angi-
ogenic effect of this vaccine depended on CD4+ T cells 
eliciting endothelial-specific antibody responses. Using a 
syngeneic vaccine consisting of fixed hepatic sinusoidal 
endothelial cells, Okaji et  al. also demonstrated potent 
preventative and therapeutic anti-tumor immunity in a 
lung metastasis model of murine colon cancer [101]. Both 
antibody and cytotoxic T cell responses against endothe-
lial cells were detected in response to this vaccine. Similar 
studies performed in animal models have reported potent 
angiogenesis inhibition and tumor targeting when using 
syngeneic endothelial cell vaccines [102, 103], xenoge-
neic endothelial cells [104], and xenogeneic endothelial 
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proteins [105]. Although the experimental design differ-
ences between these studies preclude any definitive con-
clusions concerning the optimal vaccine candidate, these 
data collectively provide a compelling proof of concept 
that tolerance to tumor endothelium can be broken using 
whole endothelial cells as vaccines.
Clinical progress with endothelial cell vaccines
HUVECs have been used in pilot studies to test the anti-
angiogenic effects of vaccination in patients with malig-
nant brain tumors and metastatic colorectal cancer 
[106, 107]. Vaccinations were performed using 5 × 10(7) 
HUVECs given intradermally on a weekly basis for 
the first month and the every 2  weeks from the second 
month onward. In a published report where a total of 230 
vaccinations were administered to 6 patients with recur-
rent malignant brain tumors and 3 patients with meta-
static colorectal cancer, MRI results showed partial or 
complete responses lasting for a minimum of 9 months in 
3 of the patients with brain tumors [106]. Moreover, anti-
bodies directed against HUVEC antigens were detected 
in eight out of nine patients and HUVEC-specific CTLs 
were detected in 6 of 7 tested patients. No adverse events 
were reported with the exception of skin reactions at the 
vaccine injection site.
In a related study, 17 patients with recurrent glio-
blastoma were treated with the HUVEC vaccine using 
the same protocol of intradermal delivery [107]. These 
patients had been previously treated with surgery and 
chemoradiotherapy, and were also undergoing salvage 
treatments including concomitant and adjuvant chem-
otherapy during the course of the study. The results 
showed that HUVEC vaccine therapy is feasible for 
recurrent glioblastoma based on significant prolonga-
tions of the tumor doubling times and reduced tumor 
growth rates at 3- and 6-month follow ups. Despite the 
fact that 352 vaccinations were performed, no adverse 
events were observed with the exception of skin reac-
tions at the injection sites. For comparative purposes, the 
investigators point out that bevacizumab, a humanized 
monoclonal antibody to VEGF, is associated with grade 
3 adverse events in 46.4  % of patients when used alone 
and in 65.8 % of patients when used in combination with 
chemotherapy [108], demonstrating that a HUVEC vac-
cine appears to be much safer than conventional anti-
angiogenesis drug therapies [107]. The authors conclude 
that, for invasive and large tumors, HUVEC vaccination 
is feasible for use in combination with other treatment 
modalities and similar trials should be conducted for 
other types of cancer.
Placental endothelial cell vaccines: advancing 
ValloVax™ for cancer treatment
Among the vaccine candidates for targeting tumor 
endothelium, the placenta is a source of significant num-
bers of proliferating and angiogenic cells owing to its 
immunological status at the maternal-fetal interface. In 
the placenta, trophoblast cells invade into the maternal 
uterine wall where they remodel the spiral arteries and 
supply angiogenic factors for de novo blood vessel forma-
tion and expansion of the pre-existing vascular network 
[109]. These processes must meet the high demands for 
blood supply and nutrient exchange of the growing fetus, 
analogous to the elaborate vascular networks required for 
tumor growth.
The idea of using placenta as a source of antigens for 
vaccination against tumors originated in the 1970s from 
Dr. Valentin Govallo who noted the immunological 
similarities between pregnancy and cancer and dem-
onstrated that immunity to placental trophoblast cells 
conferred radiological tumor reductions in lung cancer 
patients (reviewed in [110]). Indeed, a substantial body 
of literature validates numerous parallels in prolifera-
tion, angiogenesis, invasion, and immune suppression 
between cancer and pregnancy that is attributable to 
shared characteristics of fetal-derived trophoblast cells 
of the placenta and tumor cells [111]. Common angio-
genesis-associated molecules that have been identified as 
highly expressed in tumor cells and in placenta include 
VEGF family members [112], FGF/FGFR, survivin [113], 
calreticulin [114], angiomotin [115], ROBO4 [116], and 
PDGFB/PDGFR [117]. Placenta is also a practical source 
for purification of endothelial cells for therapeutic pur-
poses with yields reported from 2 to 10 billion primary 
endothelial cells per placenta [118–120]. In contrast, 
the theoretical yield of total cells from umbilical cord 
(including mesenchymal and endothelial cells) is 500 
million cells with reported yields of less than half of this 
amount following isolation and processing [121]. Pla-
cental endothelial cells are thus a feasible alternative to 
HUVECs as vaccines for targeting tumor vasculature.
Batu Biologics is currently advancing ValloVax™, a 
vaccine consisting of placenta-derived endothelial cells 
pretreated with interferon gamma to enhance immu-
nogenicity. Pre-clinical studies revealed that ValloVax™ 
potently inhibits tumor growth in 3 histologically distinct 
animal models and also suppresses pulmonary metastasis 
subsequent to intravenous tumor administration [122]. 
This new approach awaits clinical validation and may 
serve as a novel anti-angiogenesis vaccine that can be 
deployed against a variety of tumor types.
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Conclusions
Blocking tumor-induced angiogenesis has become a focal 
point for the development of new cancer therapeutic 
drugs. Vaccines represent a promising approach for over-
coming tolerance to the angiogenic factors that support 
cancer growth and metastasis. Antigens that are highly 
expressed on proliferating tumor endothelium, while 
comparatively downregulated or absent on quiescent 
endothelium in healthy tissues and during normal physi-
ological angiogenesis are ideal candidates for vaccination 
strategies targeting the tumor vasculature. Two major 
types of vaccines are being developed; namely, vaccines 
against defined angiogenesis-associated antigens, and 
whole endothelial cell vaccines. The data available thus 
far support the feasibility of these approaches for gener-
ating humoral and cell-mediated immunity against the 
tumor vasculature and the safety of endothelial cell-based 
vaccines.
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